Email this article 
The first experience of using prostate cancer organoids as a model for personalized selection of drugs
- Authors: Nikulin S.V.1,2, Alekseev B.Y.1,3, Poloznikov A.A.1,2, Osipyants A.I.1,4
-
Affiliations:
- National Medical Research Radiological Center, Ministry of Health of Russia
- National Research University “Higher School of Economics”
- Medical Institute of Continuing Education, Russian Biotechnological University
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
- Issue: Vol 19, No 2 (2023)
- Pages: 41-46
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. PROSTATE CANCER
- Published: 11.08.2023
- URL: https://oncourology.abvpress.ru/oncur/article/view/1635
- DOI: https://doi.org/10.17650/1726-9776-2023-19-2-41-46
- ID: 1635
Cite item
Full Text
Abstract
Background. A promising experimental approach to the personalized selection of treatment regimens is the study of the sensitivity of tumor cells to drugs in vitro on tumor organoids.
Aim. To generate a culture of prostate tumor organoids and to assess the effectiveness of the chemotherapeutic drug docetaxel used to treat prostate cancer on this culture.
Materials and methods. The initial tissue was dissociated using gentleMACS Octo homogenizer. Next, the cells were cultured in matrix Matrigel with addition of a serum-free complete nutrient medium. For histological analysis, organoids were fixed in a 10 % formalin solution, followed by staining with hematoxylin and eosin according to the standard protocol. Cell viability was assessed using MTS assay.
Results. In this work, we generated a new culture of prostate cancer cells. The histological analysis confirmed that the resulting organoids consist of tumor epithelial cells. As a result of the cytotoxic test, it was shown that in this case docetaxel (82.9 %; p = 0.32) didn’t reduce statistically significantly the viability of prostate cancer cells compared to the control.
Conclusion. The use of tumor organoids of prostate cancer for selection of an optimal treatment regimen is a promising experimental technology, however, further research is necessary for its introduction into practice.
Keywords
About the authors
S. V. Nikulin
National Medical Research Radiological Center, Ministry of Health of Russia;National Research University “Higher School of Economics”
Author for correspondence.
Email: snikulin@hse.ru
ORCID iD: 0000-0002-7900-5810
https://www.hse.ru/org/persons/357576526
Sergey Vyacheslavovich Nikulin
3 2nd Botkinskiy Proezd, Moscow 125284, Russia
20 Myasnitskaya St., Moscow 101000, Russia
Russian FederationB. Ya. Alekseev
National Medical Research Radiological Center, Ministry of Health of Russia;Medical Institute of Continuing Education, Russian Biotechnological University
Email: byalekseev@mail.ru
ORCID iD: 0000-0002-3398-4128
3 2nd Botkinskiy Proezd, Moscow 125284, Russia
11 Volokolamskoe Shosse, Moscow 125080, Russiа
Russian FederationA. A. Poloznikov
National Medical Research Radiological Center, Ministry of Health of Russia;National Research University “Higher School of Economics”
Email: andrey.poloznikov@gmail.com
ORCID iD: 0000-0003-1816-8699
3 2nd Botkinskiy Proezd, Moscow 125284, Russia
20 Myasnitskaya St., Moscow 101000, Russia
Russian FederationA. I. Osipyants
National Medical Research Radiological Center, Ministry of Health of Russia;Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Email: osssip@gmail.com
ORCID iD: 0000-0001-6492-5457
3 2nd Botkinskiy Proezd, Moscow 125284, Russia
1 Samory Mashela St., Moscow 117997, Russia
Russian FederationReferences
- Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. doi: 10.3322/caac.21492
- Malignant tumors in Russia in 2016 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2018. 250 p. (In Russ.).
- Sartor O., de Bono J.S. Metastatic Prostate Cancer. N Engl J Med 2018;378(7):645–57. doi: 10.1056/NEJMra1701695
- Nuhn P., De Bono J.S., Fizazi K. et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol 2019;75(1):88–99. doi: 10.1016/j.eururo.2018.03.028
- Jackson S.E., Chester J.D. Personalised cancer medicine. Int J Cancer 2015;137(2):262–6. doi: 10.1002/ijc.28940
- Drost J., Clevers H. Organoids in cancer research. Nat Rev Cancer 2018;18(7):407–18. doi: 10.1038/s41568-018-0007-6
- Gao D., Vela I., Sboner A. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014;159(1):176–87. doi: 10.1016/j.cell.2014.08.016
- Verduin M., Hoeben A., De Ruysscher D. et al. Patient-derived cancer organoids as predictors of treatment response. Front Oncol 2021;11:1–16. doi: 10.3389/fonc.2021.641980
- Liston D.R., Davis M. Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies. Clin Cancer Res 2017;23(14):3489–98. doi: 10.1158/1078-0432.CCR-16-3083
- Van de Wetering M., Francies H.E., Francis J.M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 2015;161(4):933–45. doi: 10.1016/j.cell.2015.03.053
- Sachs N., de Ligt J., Kopper O. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 2018;172(1–2): 373–86.e10. doi: 10.1016/j.cell.2017.11.010
- Weeber F., Ooft S.N., Dijkstra K.K. et al. Tumor organoids as a preclinical cancer model for drug discovery. Cell Chem Biol 2017;24(9):1092–100. doi: 10.1016/j.chembiol.2017.06.012
- Servant R., Garioni M., Vlajnic T. et al. Prostate cancer patientderived organoids: detailed outcome from a prospective cohort of 81 clinical specimens. J Pathol 2021;254(5):543–55. doi: 10.1002/path.5698
- Nikulin S.V., Alekseev B.Ya., Sergeeva N.S. et al. Breast cancer organoid model allowed to reveal potentially beneficial combinations of 3,3′-diindolylmethane and chemotherapy drugs. Biochimie 2020;179:217–27. doi: 10.1016/j.biochi.2020.10.007
- Poloznikov A., Nikulin S., Bolotina L. et al. 9-ING-41, a Small Molecule Inhibitor of GSK-3β, Potentiates the Effects of Chemotherapy on Colorectal Cancer Cells. Front Pharmacol 2021;12:1–18. doi: 10.3389/fphar.2021.777114
- Cheaito K., Bahmad H., Hadadeh O. et al. Establishment and characterization of prostate organoids from treatment-naïve patients with prostate cancer. Oncol Lett 2021;23(1):6. doi: 10.3892/ol.2021.13124
- Pamarthy S., Sabaawy H.E. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine. Mol Cancer 2021;20(1):125. doi: 10.1186/s12943-021-01426-3
Supplementary files
